NanoBio's Decision To Go OTC With Its Cold Sore Med Pays Off With GSK Deal
This article was originally published in The Pink Sheet Daily
Executive Summary
The privately-held biotech chooses a different commercial path for its proprietary product and gains validation for its nano-emulsion delivery platform, NanoStat.